Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

Could a new drug improve kidney disease treatment outcomes?

Researchers found that a new drug called Vafseo (vadadustat) may significantly lower the risk of death and hospitalization for people with anemia related to chronic kidney disease (CKD) who are on dialysis. This finding comes from a comprehensive analysis of data from the Phase 3 INNO2VATE trial, which compared Vafseo to the standard treatment, darbepoetin alfa. The results suggest that Vafseo could be a better option for managing anemia in these patients, potentially leading to improved health outcomes.

This discovery is important for individuals with CKD who are receiving dialysis and struggling with anemia, a condition that can lead to fatigue, weakness, and other serious health issues. The analysis indicated that patients treated with Vafseo experienced lower rates of death and hospitalization compared to those receiving the traditional treatment. This could mean a better quality of life and more stability for people dealing with the challenges of kidney disease.

The evidence comes from a post-hoc analysis of randomized patients in the INNO2VATE program, which is a large clinical trial. While the results are promising, it’s important to note that Vafseo has only been shown to improve outcomes in patients on dialysis and may not be suitable for everyone. The safety profile also includes some risks, such as increased blood pressure and potential liver issues, which need to be monitored.

If you or someone you know is dealing with anemia due to CKD and receiving dialysis, it may be worth discussing Vafseo with a healthcare provider. They can provide more information on whether this treatment is appropriate and how it may fit into an overall health management plan.

Source: globenewswire.com